Alterity Therapeutics (NASDAQ:ATHE) Price Target Raised to $12.00

Alterity Therapeutics (NASDAQ:ATHE) had its target price hoisted by analysts at Maxim Group from $8.00 to $12.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Maxim Group’s price target points to a potential upside of 162.58% from the stock’s current price.

Alterity Therapeutics Price Performance

Shares of Alterity Therapeutics stock traded up $1.66 during trading on Thursday, reaching $4.57. The company’s stock had a trading volume of 22,981,076 shares, compared to its average volume of 1,413,356. The firm’s 50-day moving average is $2.64 and its two-hundred day moving average is $1.80. Alterity Therapeutics has a 52-week low of $1.00 and a 52-week high of $5.87.

Institutional Investors Weigh In On Alterity Therapeutics

A hedge fund recently raised its stake in Alterity Therapeutics stock. HB Wealth Management LLC increased its stake in Alterity Therapeutics Limited (NASDAQ:ATHE) by 34.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,883 shares of the company’s stock after buying an additional 8,100 shares during the period. HB Wealth Management LLC owned 0.44% of Alterity Therapeutics worth $110,000 at the end of the most recent reporting period. 2.14% of the stock is currently owned by hedge funds and other institutional investors.

About Alterity Therapeutics

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson’s disease.